All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Results from the phase III ECHO trial (NCT02972840) of acalabrutinib (A) plus bendamustine (B) and rituximab (R) vs placebo (Pbo) plus B and R in patients with newly diagnosed mantle cell lymphoma (MCL) were presented at the European Hematology Association (EHA) 2024 Hybrid Congress by Michael Wang.1 |
Key learnings: |
The phase III ECHO trial met its primary endpoint of progression-free survival (PFS). |
With a median follow-up of 45 months (mo), the PFS was 66.4 mo vs 49.6 mo in the A+B+R and Pbo+B+R arms, respectively (p = 0.0160). |
Overall response rates were 91% (complete response [CR], 66.6%) vs 88% (CR, 53.5%) in the A+B+R and Pbo+B+R arms, respectively. |
Overall survival (OS) was not reached in the A+B+R or Pbo+B+R arms (HR, 0.86; 95% confidence interval [CI], 0.65–1.13; p = 0.2743). |
The safety profile of A+B+R was consistent with that of the individual agents. |
Gr ≥3 AEs were comparable between A+B+R and Pbo+B+R arms, and AEs of clinical interest were:
|
The ECHO trial results suggest that addition of A to B+R could improve outcomes for older patients with newly diagnosed MCL when given as a frontline therapy. |
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox